Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 196 institutions reported holding it in 13F filings for Q2 2026, worth $2.15B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Palvella Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 20 | 1 | 25 | +6 |
| Shares | 362.3K | 13.0K | 605.6K | +256.3K (+73.4%) |
| Value | $3.57M | $127.3K | $10.1M | +$6.64M (+192.8%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Palvella Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ADAR1 Capital Management, LLC | 144,641 | $2.40M | 0.40% |
| BML Capital Management, LLC | 42,130 | $698.5K | 0.41% |
| CM Management, LLC | 22,500 | $373.1K | 0.30% |
| Frazier Life Sciences Management, L.P. | 15,942 | $266.9K | 0.01% |
| BlackRock, Inc. | 12,938 | $214.5K | 0.00% |
| Citadel Advisors LLC | 11,686 | $195.6K | 0.00% |
| Truvestments Capital LLC | 14 | $232 | 0.00% |
| Danske Bank A/S | 2 | $33 | 0.00% |
Sold out (2)
Institutions that held Palvella Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 334 | $3.28K |
| Royal Bank of Canada | 4 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Palvella Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 12,975 | $127.3K |